©The Author(s) 2025.
World J Hepatol. Nov 27, 2025; 17(11): 112364
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.112364
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.112364
Figure 1 Differentially expressed genes.
A: Volcano plot showing differentially expressed genes between the response and non-response groups; B: Gene Ontology annotation analysis of highly expressed genes in the non-response group; C: Gene Ontology annotation analysis of highly expressed genes in the response group; D and E: Kaplan-Meier curves for long intergenic non-protein coding RNA 01554 (D) and whirlin (E), respectively, comparing high and low expression in the study population; F and G: Disease-specific survival for long intergenic non-protein coding RNA 01554 (F) and whirlin (G), based on high and low expression, as derived from The Cancer Genome Atlas database. LINC01554: Long intergenic non-protein coding RNA 01554; WHRN: Whirlin; TCGA: The Cancer Genome Atlas; LIHC: Liver hepatocellular carcinoma.
- Citation: Wang LJ, Cui Y, Huang LF, Zhang JQ, Zhao TT, Wang HW, Liu M, Jin KM, Wang K, Xing BC. Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma. World J Hepatol 2025; 17(11): 112364
- URL: https://www.wjgnet.com/1948-5182/full/v17/i11/112364.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i11.112364